Aug 22, 2014 at 15:37 | Source: Moneycontrol.com
Ranbaxy Laboratories has informed that a meeting of the Equity Shareholders of the Company will be held on September 19, 2014 for considering Scheme of Arrangement providing merger of the Company with Sun Pharmaceutical Industries Limited.
Jun 27, 2014 at 11:06 | Source: CNBC-TV18
There are host of players which are already there with Diovan HCT, seven players are already there in the market with a combination, so upside for Ranbaxy will be limited, says Ranjit Kapadia of Centrum Broking
May 11, 2014 at 21:05 | Source: PTI
Daiichi Sankyo, owner of Ranbaxy Laboratories Limited, has filed a petition in Andhra Pradesh High Court requesting it to vacate the 'status quo' order it issued earlier on Sun Pharma-Ranbaxy merger process.
Apr 07, 2014 at 08:36 | Source: Moneycontrol.com
Sun Pharmaceutical at its meeting held on April 06, 2014 has approved the scheme of arrangement between Ranbaxy Laboratories Limited and the Company, subject to receipt of necessary approvals, consents and filings. The Board of Directors has recommended the share exchange ratio of 8 fully paid up equity shares for every 10 equity shares of Ranbaxy.
Feb 14, 2014 at 17:24 | Source: Moneycontrol.com
Zenotech Laboratories board meeting held on February 14, 2014, has approved the following:- Appointment of Mr. Rajiv Gulati as an Additional Director of the Company with immediate effect, Mr. Rajiv Gulati is currently working as President- Global Pharmaceutical Business with Ranbaxy Laboratories Limited.
Jan 08, 2014 at 09:32 | Source: Moneycontrol.com
Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RPCI received approval on December 24, 2013 to manufacture and market RAN-Donepezil Hydrochloride 5 mg and 10 mg tablets from Health Canada.
Nov 01, 2013 at 17:17 | Source: CNBC-TV18
Rajesh Agarwal, Director - Research at Eastern Financiers Limited advises selling Ranbaxy Laboratories and buying Lupin with a target of Rs 1,015 in the next 9-12 months.
Sep 17, 2013 at 12:17 | Source: CNBC-TV18
SP Tulsian of sptulsian.com feels that Ranbaxy Laboratories may bounce back to Rs 360-370 in September series itself. There is very limited risk of going down from here and Rs 320 seems to be a good support for the stock, he adds.
Jun 10, 2011 at 15:51 | Source: Moneycontrol.com
The US Food and Drugs Administration has recommended that there should be limited use of high doses of cholesterol lowering drug Sinvastatin as the highest approved dose of 80 mg increases the risk of muscle damage, particularly during the first 12 months of use.
Mar 12, 2011 at 15:00 | Source: Moneycontrol.com
Diagnostics services provider Super Religare Laboratories proposes to enter capital market with a public issue of up to 2.8 crore equity shares of face value of Rs 10 each.